Dysport (AbobotulinumtoxinA): Clinical Guide to Botulinum Toxin Anti-Wrinkle Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

Dysport (abobotulinumtoxinA, abbreviated aboBoNTA) is a prescription botulinum toxin type A product manufactured by Galderma from cultures of Clostridium botulinum Hall strain. It is one of four commercially available botulinum toxin type A (BoNTA) products in current clinical use for aesthetic and therapeutic indications. Botulinum toxin type A inhibits the release of acetylcholine at the neuromuscular junction by cleaving the SNAP-25 protein component of the SNARE complex, thereby preventing vesicle fusion and neurotransmitter release. The resulting chemodenervation of the targeted muscle produces controlled, temporary relaxation — the basis of its anti-wrinkle, anti-hyperhidrosis, and analgesic effects.

The four major BoNTA products differ importantly in their molecular weight, complexing protein content, potency, dosing, and diffusion behaviour. Dysport (aboBoNTA) exists as a 900 kilodalton complex of the 150 kDa core neurotoxin surrounded by haemagglutinin and non-haemagglutinin accessory proteins. Botox (onabotulinumtoxinA, onaBoNTA) — manufactured by Allergan/AbbVie — also exists as a 900 kDa complex but with a different constellation of complexing proteins. Xeomin (incobotulinumtoxinA, incoBoNTA) — manufactured by Merz — is the only product containing the pure 150 kDa core neurotoxin without any complexing proteins, earning it the descriptor "naked" toxin. The absence of complexing proteins in Xeomin may theoretically reduce immunogenicity and antibody neutralisation risk over repeated treatment cycles. Jeuveau (prabotulinumtoxinA, praboBoNTA) — manufactured by Evolus — is a 900 kDa complex approved solely for glabellar line treatment in the US.

A critical clinical point is that Dysport units are not equivalent to Botox units. The dose conversion ratio between Dysport and Botox is approximately 2.5 to 3:1 (Dysport:Botox) — meaning 50 Dysport units is approximately equivalent to 20 Botox units for glabellar line treatment. Xeomin units are approximately 1:1 equivalent to Botox units. Errors in unit conversion between products have led to adverse events; prescribers switching products must apply the correct conversion ratio.

Dysport and other BoNTA products have regulatory approval for specific indications and are used extensively off-label for additional evidence-supported aesthetic and therapeutic applications.

FDA-Approved Indications for Dysport

• Glabellar lines (frown lines between the eyebrows): Dysport is FDA-approved for temporary improvement of moderate-to-severe glabellar lines in adults up to age 65. The pivotal IDEAL trial demonstrated a 74% responder rate (defined as none or mild glabellar line severity) at 30 days with Dysport versus 22% with placebo. Approved dose: 50 Dysport units (split across five injection points in the corrugator supercilii and procerus muscles). Duration of effect: three to four months.
• Cervical dystonia: FDA-approved for reduction of abnormal head position and neck pain in cervical dystonia in patients 18 years and older. Doses range from 250 to 1,000 units depending on muscle mass and severity.
• Spasticity: FDA-approved for lower and upper limb spasticity in adults and children (two years and older for lower limb). Significant dose ranges (200–1,500 units) reflect the larger muscle mass involved.
• Primary axillary hyperhidrosis: FDA-approved for treatment of primary axillary hyperhidrosis in adults. The multicentre SWEAT trial demonstrated significant and sustained reduction in axillary sweating with Dysport 100 units per axilla.

Off-Label Aesthetic Applications (Evidence-Based)

• Frontalis (forehead lines): Horizontal forehead lines from frontalis contraction. Dysport is particularly well-suited to the forehead because its slightly wider diffusion pattern requires fewer injection points to achieve uniform muscle relaxation. Typical dose: 10–20 Dysport units in 3–5 injection points across the forehead. Caution: excessive frontalis weakening causes brow ptosis; at least 2 cm clearance from the supraorbital rim is maintained.
• Lateral orbital lines (crow's feet): Periorbital lines from orbicularis oculi contraction. Dose: 15–30 Dysport units per side in 3 injection points lateral to the orbital rim.
• Platysmal bands (neck cords): Nefertiti lift — injecting along platysma bands and along the jawline reduces downward pull on the lower face, improving jawline definition.
• Masseter hypertrophy (bruxism and facial slimming): Masseter muscle reduction with BoNTA reduces jaw clenching pain and produces a more oval lower facial contour. Doses of 40–80 Dysport units (20–30 Botox equivalents) per masseter muscle, repeated every six months initially then annually for maintenance.
• Palmar and plantar hyperhidrosis: Off-label; palmar injections require median nerve block (or other regional anaesthesia) for pain control due to the density of sweat glands and pain sensitivity of the palm. Requires higher doses (80–120 Dysport units per palm).

Therapeutic (Non-Aesthetic) Off-Label Applications

• Chronic migraine (onaBoNTA — PREEMPT protocol): The PREEMPT-1 and PREEMPT-2 randomised trials established onabotulinumtoxinA (Botox) 155 units at 31 injection sites across seven head and neck muscle groups as effective prophylaxis for chronic migraine (15 or more headache days per month). This indication is approved for onaBoNTA (Botox) specifically; Dysport is used off-label for migraine prevention with evidence extrapolated from the BoNTA class.
• Sialorrhoea (drooling): Parotid and submandibular gland injection for excessive salivation in neurological conditions (Parkinson's, motor neurone disease, cerebral palsy).

Appropriate patient selection is essential for achieving optimal outcomes with Dysport and other BoNTA products. A thorough facial and medical assessment by a qualified practitioner guides product choice, dose, and injection technique.

Ideal Candidates for Aesthetic BoNTA Treatment

• Adults aged 18–65 with dynamic facial lines (lines that appear or deepen with muscle contraction) in the upper face — glabellar complex, forehead, and periorbital areas
• Patients with realistic expectations: BoNTA reduces the appearance of dynamic lines and prevents static line deepening with regular use; it does not restore lost facial volume or eliminate deep static lines without adjunct filler treatment
• Patients who understand that results are temporary (three to four months duration) and commit to retreatment schedules
• Good general health without neuromuscular junction disease or relevant drug interactions

Contraindications

• Neuromuscular junction disorders: Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis (ALS), and other disorders of neuromuscular transmission are absolute contraindications. Botulinum toxin may exacerbate respiratory and swallowing muscle weakness in these conditions, potentially causing life-threatening respiratory compromise.
• Aminoglycoside antibiotics (gentamicin, tobramycin, neomycin): Enhance the neuromuscular blocking effect of BoNTA — potentiate weakness beyond intended treatment zone. Relative contraindication; defer elective BoNTA injections until antibiotic course is completed.
• Pregnancy and lactation: Botulinum toxin products are Category C drugs in pregnancy; elective aesthetic treatment should be deferred. No data on breast milk transfer.
• Allergy to human serum albumin or lactose: Dysport formulation contains human serum albumin and lactose; absolute contraindication in confirmed allergy.
• Active infection at injection site: Defer treatment until resolved to avoid haematogenous spread.
• Unrealistic expectations or body dysmorphic disorder: Thorough pre-treatment consultation to assess patient motivation and identify body dysmorphia, which is a contraindication to elective aesthetic procedures.

Special Populations

Patients over 65 years of age may experience longer duration of effect from BoNTA due to age-related reduction in neuromuscular junction turnover rate. Lower doses are recommended for initial treatment in older patients to avoid excessive weakness or prolonged effect in the frontalis, which can impair brow elevation. Patients with significant brow ptosis at baseline should not receive frontalis injections as this will worsen the appearance of upper eyelid hooding. Periorbital injection in patients with significant lower eyelid laxity (snap test positive) requires caution to avoid lower eyelid ectropion from orbicularis weakening.

The four available BoNTA products share the same mechanism of action but differ in molecular characteristics, potency, dosing units, diffusion behaviour, immunogenicity profile, and clinical applications. Understanding these differences is essential for product selection and dose conversion.

Molecular and Pharmacological Comparison

• Dysport (aboBoNTA, Galderma): 900 kDa complex; 2.5:1 dose ratio versus Botox (approximately); slightly higher diffusion radius due to lower protein-to-toxin ratio in some preparations. Reconstituted with 1.0–2.5 mL of 0.9% sodium chloride per 300-unit vial. The IDEAL trial demonstrated 74% responder rate for glabellar lines at 30 days. Onset of action 24–72 hours; peak effect at day 14; duration three to four months for glabellar lines.
• Botox (onaBoNTA, Allergan/AbbVie): 900 kDa complex; the original clinically used BoNTA product with the largest clinical evidence base across all indications. Reconstituted with 1–4 mL of 0.9% sodium chloride per 100-unit vial (most aesthetic applications use 2–2.5 mL). PREEMPT-approved protocol for chronic migraine: 155 units at 31 sites. Reference product for unit conversion with all other BoNTA products.
• Xeomin (incoBoNTA, Merz): 150 kDa pure neurotoxin — no complexing proteins. FDA-approved for glabellar lines, cervical dystonia, blepharospasm, and upper limb spasticity. Xeomin units are approximately 1:1 equivalent to Botox units. The absence of complexing proteins may theoretically reduce the formation of neutralising antibodies with repeated use — particularly relevant for high-dose therapeutic applications (cervical dystonia, spasticity) where antibody-mediated secondary non-response is a clinical problem. Does not require refrigeration prior to reconstitution (room temperature stable).
• Jeuveau (praboBoNTA, Evolus): 900 kDa complex; FDA-approved solely for glabellar lines in the US (approved 2019). Clinical trial data demonstrate non-inferiority to onaBoNTA for glabellar line responder rates. Priced competitively below Botox and Dysport in some US markets.

Diffusion Properties and Clinical Implications

Dysport has a slightly larger effective diffusion radius compared to Botox at equivalent biological doses, which has clinical implications for both efficacy and safety. In the forehead, wider diffusion is an advantage — fewer injection points achieve uniform frontalis relaxation without the linear banding that can occur with tight-spacing Botox injections. However, in the periorbital region and glabellar complex, wider spread requires careful placement to avoid diffusion into the levator palpebrae superioris muscle (causing upper eyelid ptosis) or superior oblique muscle (causing diplopia). The 1–2 cm minimum clearance from the supraorbital rim and medial canthal tendon should be maintained when injecting the glabellar complex with Dysport.

Reconstitution of Dysport

Dysport is supplied as a lyophilised powder in 300-unit and 500-unit vials. For facial aesthetic applications, reconstitution with 1.5–2.5 mL of preservative-free 0.9% sodium chloride is typical, producing a concentration of 120–200 units per mL. Preserved saline (bacteriostatic, containing 0.9% benzyl alcohol) is used by some practitioners to reduce injection discomfort without loss of efficacy; non-preserved saline remains the approved diluent. Reconstituted toxin should be stored refrigerated at 2–8°C and used within 24 hours; some centres report maintained bioactivity up to 72 hours under refrigeration, though this is off-label.

Hyperhidrosis Treatment Technique

For primary axillary hyperhidrosis, Minor's starch-iodine test is performed before treatment to map the distribution of active sweat glands. Iodine solution is applied to the dry axillary skin and allowed to dry; corn starch powder is applied over the iodine; the starch-iodine complex turns dark blue or purple in areas of active sweating. Injection grid points (approximately 1–1.5 cm apart, 10–15 points per axilla) are marked within the staining zone. Dysport 100 units per axilla is injected intradermally using a 30G needle at each grid point. Duration of hyperhidrosis control with Dysport: approximately four to six months in axillary application.

Dysport and the BoNTA product class are among the most extensively studied aesthetic and therapeutic injectables in medicine. The clinical evidence base spans multiple randomised controlled trials, long-term safety registries, and post-approval surveillance data.

Aesthetic Benefits — Efficacy Data

• Glabellar lines (IDEAL trial): The pivotal IDEAL randomised, double-blind, multicentre trial enrolled 816 adults with moderate-to-severe glabellar lines and demonstrated a 74% responder rate (none or mild severity at maximum frown) with Dysport 50 units versus 22% with placebo at day 30. The onset of effect was detected as early as day 2 in some subjects. The trial confirmed a three-month duration of treatment effect in the majority of responders.
• Forehead and periorbital lines: Phase III data across multiple BoNTA products (extrapolated to Dysport given mechanism equivalence) demonstrate 85–95% patient satisfaction with appropriate dosing. The forehead advantage of Dysport (fewer injection points due to wider diffusion) is documented in comparative practitioner surveys.
• Longitudinal benefit — prevention of static line formation: Observational studies demonstrate that patients who begin BoNTA treatment before deep static lines become established prevent the conversion of dynamic lines to permanent static rhytids. This prevention benefit compounds over time — long-term users (5 or more years) show measurably fewer deep static lines at treated sites than matched non-treated controls.

Therapeutic Benefits

• Primary axillary hyperhidrosis: BoNTA reduces axillary sweating by an average of 80–90% at four weeks. Quality of life instruments (DLQI, HDSSv) show significant improvement in social functioning, clothing choice, and self-confidence. Duration of effect (approximately four to six months) is longer in axillary hyperhidrosis than in cosmetic facial applications.
• Chronic migraine prophylaxis (PREEMPT — onaBoNTA): The PREEMPT-1 and PREEMPT-2 trials each demonstrated a significant reduction in headache days per month (approximately 8–9 fewer headache days per month vs 6–7 with placebo at 24 weeks) with onaBoNTA 155 units. Three consecutive quarterly treatment sessions are typically required before maximum prophylactic benefit is achieved.
• Cervical dystonia and spasticity: BoNTA is a first-line treatment for cervical dystonia and adult upper and lower limb spasticity, where it significantly reduces pain, improves range of motion, and reduces caregiver burden in neurologically impaired patients.

Safety Profile

BoNTA products have an excellent long-term safety profile at approved doses. No systemic toxicity has been documented at therapeutic aesthetic doses. The most significant safety signal associated with BoNTA as a class — distant spread of toxin effect causing dysphagia, dysphonia, and respiratory compromise — occurs almost exclusively at the high therapeutic doses used for spasticity, dystonia, and sialorrhoea treatment, not at the low doses used for facial aesthetics.

While botulinum toxin type A products are among the safest aesthetic injectables when used at approved doses by trained practitioners, a defined set of adverse effects and risks must be discussed with every patient during informed consent.

Local Injection-Site Reactions (Common, Self-Limiting)

• Bruising: Most common at injection sites, especially periorbital. Aspirin and NSAIDs should be discontinued five to seven days before treatment where safe to do so. Topical arnica and cold compresses reduce bruising duration.
• Erythema and oedema at injection sites: Transient, resolves within 24–48 hours.
• Headache: Occurs in 10–15% of patients following glabellar treatment, typically in the first 24–48 hours. Managed with over-the-counter analgesia.

Aesthetic Complications (Dose and Technique Dependent)

• Eyelid ptosis: The most concerning aesthetic complication of glabellar complex injection. Caused by diffusion of toxin to the levator palpebrae superioris muscle through the orbital septum. Incidence approximately 1–3% in published series; risk reduced by maintaining 1 cm minimum clearance from the supraorbital rim, not injecting medially near the corrugator, and using conservative volumes. Treated with apraclonidine 0.5% eye drops (alpha-adrenergic agonist — activates Muller's muscle, lifting the eyelid 1–3 mm) until the toxin effect wears off (six to twelve weeks).
• Brow ptosis: Excessive frontalis weakening causing brow descent and upper eyelid hooding. Particularly problematic in patients with pre-existing low brow position. Prevention requires conservative frontalis dosing and maintaining brow elevation capacity by leaving the upper frontalis (above the horizontal midpoint between brow and hairline) partially untreated.
• Diplopia: Very rare complication from diffusion to extraocular muscles. Occurs almost exclusively with periorbital injections placed too close to the medial canthal tendon (affecting superior oblique) or too low along the orbital floor. Management is conservative; resolves as toxin effect wears off.
• Asymmetry: Unequal brow or lid position from unequal doses or asymmetric anatomy. Review at two weeks; minor asymmetry can be corrected with additional small-dose injection to the undertreated side.
• Dysport-specific — spread to adjacent muscles: Dysport's wider diffusion radius compared to onaBoNTA means dosing near the brow depressor complex or medial glabellar area must be particularly conservative to avoid upper eyelid ptosis.

Antibody Neutralisation — Secondary Treatment Failure

Repeated injections of BoNTA products can lead to formation of neutralising antibodies against the botulinum toxin proteins. Once neutralising antibodies develop, injections produce no clinical effect (secondary non-response). Antibody formation is most clinically relevant at high therapeutic doses used for cervical dystonia and spasticity (reported in 3–10% of patients over time). At the low doses used for facial aesthetics, clinically significant antibody neutralisation is uncommon. Xeomin (incoBoNTA — pure 150 kDa naked toxin without complexing proteins) has the lowest theoretical immunogenicity profile and may be considered for patients who have experienced secondary non-response to complexed BoNTA products, or as a first-choice product in patients requiring high cumulative lifetime doses.

Class Warning: Distant Spread of Toxin Effect

All botulinum toxin products carry an FDA Boxed Warning regarding the risk of distant spread of toxin effect, causing dysphagia, dysphonia, diplopia, blurred vision, dysarthria, urinary incontinence, and breathing difficulties. These effects have primarily been reported at high therapeutic doses for spasticity and are not documented at aesthetic doses. Nevertheless, practitioners must counsel all patients regarding this warning and instruct them to seek immediate medical attention if swallowing difficulties, speech problems, or breathing difficulties develop after any BoNTA injection.

Structured follow-up after botulinum toxin injection enables early identification of complications, assessment of treatment response, and optimal planning for retreatment intervals — the key variables that determine long-term aesthetic outcomes.

Post-Treatment Instructions (Days 0–14)

• Immediately after injection: Patients may return to normal activities, but should avoid rubbing or massaging the injected area for four hours to prevent toxin spread to unintended muscles. Avoid lying face-down or inverted positions (yoga headstands, facial massage) for four hours.
• Exercise restriction: Vigorous exercise raises facial blood flow and is associated with increased bruising risk; patients are advised to avoid intense exercise for six hours post-treatment.
• Skin care: Topical retinoids and chemical exfoliants should be avoided at injection sites for 24 hours. Mineral make-up can be applied one hour post-injection using a gentle patting technique.
• Onset monitoring: Dysport typically shows early relaxation of the glabellar complex at 24–72 hours, with full effect established by day 14. Patients should be counselled that the maximal aesthetic result is not apparent for two weeks and should not return for touch-up assessment before this point.

Two-Week Review Appointment

A two-week follow-up appointment is standard practice in aesthetic botulinum toxin clinics. At this review, the practitioner assesses: brow position (symmetry and height), glabellar line severity at maximal frown, frontalis and orbicularis response, and whether the dose achieved the intended effect. Photographs taken at baseline, at maximum frown at baseline, and at the two-week relaxed and frowning position allow objective comparison. Minor asymmetries from differential muscle response or asymmetric baseline anatomy can be corrected with small supplementary doses at this visit. The two-week review is important for dose optimisation in new patients; it is less critical in patients with an established treatment history and known response profile.

Retreatment Intervals and Long-Term Planning

The clinical duration of Dysport effect for glabellar lines is three to four months in pivotal trial data; many patients notice a gradual return of movement from three months and schedule retreatment at twelve to sixteen weeks. Retreatment should be deferred until some muscle movement has returned to avoid cumulative muscle weakening and the theoretically increased antibody risk from over-frequent high-dose injections. Retreatment intervals of twelve weeks or more are recommended. For hyperhidrosis, axillary effect persists four to six months. For therapeutic cervical dystonia and spasticity, retreatment is scheduled at twelve to sixteen-week intervals or when clinical effect wanes. For chronic migraine prophylaxis (onaBoNTA), the PREEMPT protocol specifies twelve-weekly retreatment for at least three cycles to assess maximum prophylactic benefit.

Managing Reduced Treatment Response Over Time

A small proportion of aesthetic patients experience reduced treatment duration or effect after multiple injection cycles, potentially due to antibody formation or toxin tolerance. In this situation: consider switching to Xeomin (incoBoNTA) for its lower immunogenicity profile; increase the interval between treatments to allow antibody levels to diminish; adjust dose; or refer to a dermatologist or neurologist with expertise in BoNTA resistance management.

Botulinum toxin treatment costs are structured primarily around the product used, the number of units injected, the number of areas treated, and the practitioner and facility setting. Pricing models vary between per-unit charging (common in the UK and aesthetics-focused clinics) and per-area charging (common in the US and many international markets).

Approximate Pricing by Region and Product

• United States (Dysport): USD 4–7 per unit wholesale cost; clinic retail pricing typically USD 12–20 per unit. A standard glabellar treatment (50 Dysport units) costs USD 600–1,000. Full upper face treatment (glabellar + forehead + crow's feet; approximately 100–150 Dysport units) costs USD 1,200–2,500 depending on provider and clinic setting. Medical spa and aesthetic clinic pricing is generally lower than physician dermatology or plastic surgery clinic pricing, though practitioner training varies.
• United States (Botox, comparator): USD 10–20 per unit retail; USD 200–400 per area. Total upper face treatment: USD 600–1,500.
• United Kingdom: GBP 150–400 for glabellar lines (20 Botox units equivalent); GBP 350–700 for full upper face. Dysport is priced similarly to onaBoNTA on a per-treatment-area basis. CQC-registered aesthetic clinics charge GBP 200–600 per full upper face treatment.
• India: USD 80–250 for full upper face botulinum toxin treatment at accredited dermatology and aesthetic medicine clinics. Mumbai, Delhi, Bangalore, and Chennai have highly experienced aesthetic medicine practitioners offering international-standard treatment at 70–80% cost reduction versus Western markets.
• Thailand and Singapore: USD 150–450 for full upper face treatment at private hospitals. Bangkok and Singapore have extensive aesthetic medicine infrastructure serving both domestic and medical tourism patients.
• Turkey: USD 100–350 for full upper face treatment at private aesthetic clinics in Istanbul and Ankara.

Hyperhidrosis and Therapeutic Treatments

• Axillary hyperhidrosis (both axillae, Dysport 200 total units): USD 800–1,500 in the US; USD 150–400 in India. Some insurance plans in the US and UK (NHS prior approval) cover axillary hyperhidrosis treatment when conservative management has failed.
• Chronic migraine (onaBoNTA PREEMPT — Botox 155 units per session): USD 300–600 per session in the US for the medication alone; covered by Medicare, Medicaid, and most private insurers after a six-month trial period of oral preventive medications. NHS England funds Botox for chronic migraine through specialist neurology or headache clinics.

Value Considerations for Medical Tourism

Aesthetic botulinum toxin treatment is one of the most cost-effective treatments to seek internationally. The products available in India, Thailand, Turkey, and Mexico (Botox, Dysport, Xeomin) are the same FDA/EMA-approved formulations as used in Western markets. Patients travelling for cosmetic treatment should budget for return travel for retreatment every three to four months, which affects the overall cost calculation. Combining botulinum toxin retreatment with other elective procedures during medical tourism visits optimises the cost per visit.

Botulinum toxin is the gold-standard treatment for dynamic facial lines, but alternatives exist for patients who cannot receive BoNTA injections or who prefer non-injection options. Each alternative has a distinct mechanism, evidence base, and efficacy profile.

Alternative BoNTA Products Within the Class

If Dysport is unavailable, contraindicated, or has produced secondary non-response due to antibody formation, the clinical alternatives within the BoNTA class are onabotulinumtoxinA (Botox), incobotulinumtoxinA (Xeomin), and prabotulinumtoxinA (Jeuveau). Xeomin is the preferred switch for patients with suspected antibody-mediated non-response, given its pure neurotoxin formulation without complexing proteins. All three products work by the same mechanism and differ in dosing, formulation, and diffusion characteristics rather than clinical applications. The prescriber must apply the correct unit conversion ratio when switching between products.

Topical Neuromodulators

Topical botulinum toxin (RT002 — daxibotulinumtoxinA topical gel) has been studied in Phase II trials for crow's feet and forehead lines, with modest efficacy data demonstrating reduced dynamic line severity versus placebo. Topical application avoids injection discomfort but has substantially lower efficacy than intradermal injection. Topical retinoids (tretinoin 0.025–0.1%) applied nightly reduce fine surface lines by stimulating collagen synthesis and increasing epidermal cell turnover; they cannot relax dynamic muscles but improve overall skin texture as a complementary treatment.

Dermal Fillers (For Static Lines)

Hyaluronic acid fillers are appropriate for static lines — wrinkles that are present at rest without muscle contraction. BoNTA is appropriate for dynamic lines — those that appear or deepen with muscle movement. Many patients have both dynamic and static components to facial lines and benefit from combination treatment with both BoNTA (neuromodulator) and HA filler. For deep glabellar furrows that persist at rest after BoNTA treatment, a small amount of HA filler injected into the residual static crease produces superior correction compared to BoNTA alone.

Energy-Based Devices

• Radiofrequency microneedling (Morpheus8, Fractora): Stimulates dermal collagen remodelling to improve skin laxity and superficial lines. Does not relax muscles but improves skin quality. Two to three sessions; additive benefit with BoNTA.
• Focused ultrasound (Ultherapy/HIFU): Targets deep dermis and SMAS; produces brow lifting and mid-face tightening. Complements BoNTA by addressing tissue laxity that neuromodulators cannot correct.
• Fractional CO2 or Er:YAG laser resurfacing: Ablates and resurfaces the epidermis and superficial dermis; significantly reduces perioral and periorbital fine lines. Requires five to seven days' downtime but delivers resurfacing benefit beyond what injectable treatments can achieve for epidermal textural irregularity.

Surgical Alternatives

Upper blepharoplasty (surgical removal of excess upper eyelid skin) addresses upper eyelid hooding that BoNTA-induced brow lifting cannot correct when significant dermatochalasis exists. Brow lift (endoscopic or open) elevates the brow position structurally for patients in whom repeated BoNTA is insufficient to maintain brow position. These surgical options are discussed with a board-certified oculoplastic surgeon or facial plastic surgeon after conservative non-surgical options have been optimised.